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Abstract: The detection and identification of botulinum neurotoxins (BoNT) is complex due to
the existence of seven serotypes, derived mosaic toxins and more than 40 subtypes. Expert
laboratories currently use different technical approaches to detect, identify and quantify BoNT, but
due to the lack of (certified) reference materials, analytical results can hardly be compared. In this
study, the six BoNT/A1–F1 prototypes were successfully produced by recombinant techniques,
facilitating handling, as well as improving purity, yield, reproducibility and biosafety. All six
BoNTs were quantitatively nicked into active di-chain toxins linked by a disulfide bridge. The
materials were thoroughly characterized with respect to purity, identity, protein concentration,
catalytic and biological activities. For BoNT/A1, B1 and E1, serotypes pathogenic to humans,
the catalytic activity and the precise protein concentration were determined by Endopep-mass
spectrometry and validated amino acid analysis, respectively. In addition, BoNT/A1, B1, E1
and F1 were successfully detected by immunological assays, unambiguously identified by mass
spectrometric-based methods, and their specific activities were assigned by the mouse LD50
bioassay. The potencies of all six BoNT/A1–F1 were quantified by the ex vivo mouse phrenic nerve
hemidiaphragm assay, allowing a direct comparison. In conclusion, highly pure recombinant BoNT
reference materials were produced, thoroughly characterized and employed as spiking material in
a worldwide BoNT proficiency test organized by the EQuATox consortium.
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1. Introduction
Six different Clostridium (C.) species (Groups I–VI) produce seven different serotypes of
botulinum neurotoxins (BoNT/A–G) as their major pathogenic factors [1]. BoNTs constitute the most
deadly poisons, as parenteral uptake of nanogram quantities is lethal to human beings. Naturally,
an accidental intoxication via food contaminated with BoNT causes the disease botulism, a flaccid
paralysis of the striated muscles, finally leading to respiratory failure. Besides, their misuse as a bio
weapon, as well as very successful use as licensed drugs for the treatment of many neurological
and non-neurological disorders have been described in detail [2,3]. BoNT/A–G occur in many
variants called subtypes and mosaic toxins, i.a., due to horizontal gene transfer [1,4]. This large
diversity and extraordinary potency complicates their detection enormously [5]. To survive the
harsh conditions of the gastrointestinal tract upon oral administration, the 150 kDa BoNTs are
accompanied by up to four different, non-toxic neurotoxin-associated proteins (NAPs) in so-called
progenitor toxin complexes (PTC) of different sizes (300–760 kDa) [1]. Different variants of a
140 kDa non-toxic non-hemagglutinin protein (NTNHA) form a pH-dependent 1:1 complex (M-PTC)
with BoNT, thereby shielding each other against acidic pH and proteolytic degradation [6,7].
Additionally, hemagglutinins form a dodecameric sub-complex, which binds to the M-PTC of
BoNT/A1, B, C, D and G yielding the large L-PTC, assists in intestinal adhesion and resorption of
BoNT [8–11]. The BoNTs are classical AB protein toxins, which are produced as single polypeptide
chains (sc) and posttranslationally proteolyzed within an 8–22mer peptide loop rich in basic
amino acids (AA) to become functionally active. C. botulinum of Groups I, III and IV express
appropriate proteases, whereas strains of Groups II, V and VI lack this activity and release
only scBoNT, which receives its essential activation partially by host proteases. The di-chain
BoNT comprises a 50 kDa enzymatically-active light chain (LC) and a 100 kDa heavy chain
(HC), which mediates specific receptor recognition on neuronal surfaces, productive uptake and
translocation of LC into the neuronal cytosol. Here, the disulfide bridge covalently connecting
LC and HC is reduced, the LC liberated and able to specifically hydrolyze one of the three
soluble N-ethylmaleimide-sensitive factor attachment protein receptor (SNARE) proteins, resulting
in blockade of neuroexocytosis [12]. Synaptobrevin/vesicle-associated membrane protein (VAMP)-1
and -2 represent the substrates for BoNT/B, D, F, G and tetanus neurotoxin (TeNT), whereas BoNT/A,
C and E cleave the synaptosomal-associated protein of 25 kDa (SNAP-25). In addition, BoNT/C is
capable of hydrolyzing the isoforms syntaxin-1A/C, -1B, -2 and -3. Except for BoNT/B and TeNT,
hydrolysis occurs in unique positions and requires long stretches of 20–50 residues upstream of the
individual scissile bond for optimal cleavage of substrate peptides [13].
While different technologies for BoNT analysis have been established, hardly any universally
agreed “gold standards” are available nor have “best practices” been identified in international
proficiency tests (PT) [5,14]. Furthermore, no certified reference materials (RM) are currently
available, and no inter-laboratory exercises have been performed focusing on the detection of
BoNTs from real sample materials. Therefore, it is hardly possible to compare analytical results
obtained in different laboratories. Against this background, a central aim of the EC-funded project
EQuATox (www.equatox.eu) was to provide an evaluation of existing methods regarding screening
and identification of BoNTs by conducting an international PT. Due to the unavailability of qualified
BoNT RM, appropriate material had to be produced and thoroughly characterized to serve the BoNT
PT [15].
The selection of relevant sero- and subtypes out of the >40 BoNT variants as RMs was
guided by available epidemiological data. Statistical analysis of laboratory-confirmed human
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botulism cases by the U.S., National Botulism Surveillance from 2000 to 2014 revealed that BoNT/A
accounted for 50.7%, BoNT/B for 43.5%, BoNT/E for 3.5% and BoNT/F for 1.3% of the 2159 cases
(www.cdc.gov). No human cases were attributed to BoNT/C, D and G. Food-borne botulism in the
U.S. is predominantly caused by BoNT/A (58.6%) and BoNT/E (28.9%), whereas wound botulism
is evoked in 91.7% of cases by BoNT/A and 4.9% by BoNT/B. On the contrary, the major cause of
infant botulism is BoNT/B (58.7%), followed by BoNT/A (40.5%) and BoNT/F (0.7%). In summary,
BoNT/A, B, E and, to a lesser extent, BoNT/F are relevant for diagnostics of human botulism. In
addition, BoNT/C, D and their mosaics produced by C. botulinum Group III are dominating in large
outbreaks of animal botulism [16–19]. Therefore, it was decided to produce RM of BoNT/A, B and E
with high priority followed by BoNT/F, C and D, whereas BoNT/G was considered to be negligible.
With respect to subtypes, in the absence of representative epidemiological data, the corresponding
prototype of each serotype was chosen, i.e., BoNT/A1, B1, E1, F1, C and D.
Depending on genomic and strain background, as well as environmental conditions, like
pH, temperature, redox state, etc., the large BoNT family can occur as sc- or di-chain BoNT, as
150 kDa pure BoNT, as 300 kDa M-PTC in varying NTNHA-BoNT combinations or as L-PTCs
of up to 760 kDa. This enormous diversity of molecules complicates not only the detection of
BoNT in complex matrices, but also the selection of the relevant entity to be produced as RM.
The smallest, but fully-functional and well-defined entity constitutes the 150 kDa di-chain BoNT,
which was therefore chosen to serve as RM. Sufficient stability of pure BoNT is, e.g., demonstrated
by the pharmaceutical product incobotulinumtoxin A comprising only the pure 150 kDa BoNT/A
as the active pharmaceutical ingredient. It demonstrates a shelf-life of currently 3–4 years at
room temperature in contrast to abobotulinumtoxinA and onabotulinumtoxinA comprising the
L-PTC/A with only a 2–3-year shelf-life at 2–8 ˝C [20]. The BoNT RMs were synthesized by
means of recombinant techniques in Escherichia coli, which facilitates handling of genetically-modified
microorganisms (GMMO) with respect to biosafety and allows reproducible culturing. Furthermore,
it improves protein yield due to the overexpression of the gene of interest with optional optimization
of codon usage, as well as purity, due to affinity chromatography, and it provides fully-controlled
posttranslational proteolytic activation to obtain maximum active BoNT. Subsequently, the highly
purified BoNT were characterized thoroughly by various analytical methods with respect to
purity, maturation, identity, protein content, in vitro catalytic activity, ex vivo potency and in vivo
biological activity.
In this study, highly purified 150 kDa proteins of BoNT/A1–F1 were successfully produced and
characterized to serve as RM. They qualified to serve as the spiking material for the conduction of an
international BoNT PT organized by the EQuATox consortium [15].
2. Materials and Methods
2.1. Production of BoNT Proteins
Full-length neurotoxins were produced under biosafety level 2 containment (Project Number
GAA A/Z 40654/3/123) recombinantly in K12 E. coli strains. Employing the C-terminal His6tag,
proteins were purified on Co2+-Talon matrix (Takara Bio Europe S.A.S., Saint-Germain-en-Laye,
France) and eluted with 50 mM Tris-HCl, pH 8.0, 150 mM NaCl, 250 mM imidazole. Employing the
C-terminal Streptag, proteins were purified on StrepTactin-sepharose matrix (IBA GmbH, Göttingen,
Germany) and eluted by 10 mM desthiobiotin (IBA GmbH) in 100 mM Tris-HCl, pH 8.0. For
proteolytic activation, BoNT was incubated for 16 h at room temperature with 0.01 U bovine
thrombin (Sigma-Aldrich Chemie GmbH, Steinheim, Germany) per µg BoNT. Subsequent gel
filtration (Superdex-200 16/60 column, GE Healthcare, Freiburg, Germany) was performed in PBS,
pH 7.4. In contrast to all other serotypes, BoNT/F tend to show precipitation and loss of activity
upon freeze-thaw cycles, which was resolved by supplementing BoNT/F with 0.1% BSA. Highly
purified proteins were shock frozen in liquid nitrogen and kept at ´70 ˝C. Aliquots of the highly
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purified recombinant BoNT/A, B and E supplied to Robert Koch Institute (RKI) for spiking the BoNT
PT samples were supplemented with 0.1% BSA, leading to altered protein concentrations (BoNT/A,
0.093 mg/mL; BoNT/B, 0.017 mg/mL; BoNT/E, 0.124 mg/mL).
For analysis, highly purified proteins were denatured under reducing and non-reducing
conditions [21], subjected to 10% SDS-PAGE and detected by Coomassie brilliant blue staining.
Additionally, identical samples were run by SDS-PAGE, transferred to a nitro cellulose membrane
(GE Healthcare) and detected by mouse anti-His6 monoclonal antibody (mAb) (1:1000; Qiagen,
Hilden, Germany), goat anti-mouse-HRP (1:10,000; Thermo Fisher Scientific Germany BV & Co KG,
Braunschweig, Germany) and Pierce ECL Western Blotting Substrate (Thermo Fisher Scientific) in a
Western blot experiment.
2.2. Protein Analysis by Capillary Gel Electrophoresis (CGE)
BoNT purity analysis and quantification were performed with CGE, a semi-automated
electrophoresis system (Experion, Bio-Rad, Hercules, CA, USA), according to the manufacturer’s
protocol using bovine gamma globulin (BGG) as an external calibration protein. In short, 4 µL of
sample were mixed with 2 µL of sample buffer containing detergent and two reference proteins for
mass calibration and were loaded to the chip after a short incubation. Native and reduced samples
were analyzed in triplicates.
2.3. Peptide Sequencing by Liquid Chromatography-Tandem Mass Spectrometry (LC-MS/MS)
Trypsin digests of BoNT were analyzed by LC-MS/MS. Prior to the digestion, the BoNTs were
precipitated by methanol as described elsewhere [22], and 50 mM ammonium bicarbonate buffer and
a 1:20 weight ratio of sequencing grade trypsin (Promega, Madison, WI, USA) were added directly to
the dried protein pellet. No reduction or alkylation was performed, and the samples were digested
for 80 min at 45 ˝C. The reactions were terminated by adding formic acid, and the concentration was
adjusted to approximately 200 fmol/µL before LC-MS/MS-analysis. Standard conditions for peptide
analysis using a nano-LC coupled to a Q-TOF mass spectrometer (Waters, Milford, MA, USA) were
used (described in [22]).
2.4. Immunological Detection by Indirect Enzyme-Linked Immuno Sorbent Assay (ELISA)
MaxiSorp microtiter plates (Nunc-Immuno Microwell plate, Sigma-Aldrich, Munich, Germany)
were coated with recombinantly-expressed BoNT/A, B, E or F (500 ng/mL) in 50 µL PBS/0.1% BSA
overnight at 4 ˝C and blocked with casein buffer (Diavita, Heidelberg, Germany) for 1 h at room
temperature. Following washing, 50 µL of antibody (10 µg/mL; anti-BoNT/A: mouse mAb A709,
HCA78, A1688 and polyclonal chicken IgY HA29; anti-BoNT/B: mouse mAb B279 and polyclonal
chicken IgY HB46; anti-BoNT/E: mouse mAb E136 and polyclonal chicken IgY HE57; anti-BoNT/F:
mAb F220 and polyclonal chicken IgY HF58 [23–26]; polyclonal horse trivalent anti-BoNT/A, B and E
Botulism-Antitoxin Behring (Novartis Vaccines and Diagnostics GmbH, Marburg, Germany); “mix”:
a polyclonal mouse antiserum detecting BoNT/A, B, E and F (RKI)) were added and incubated for 2 h
at room temperature. The ELISA was developed by incubation with HRP-labeled secondary antibody
diluted in casein buffer (1 h, room temperature). Finally, the plates were washed five times with
PBS/0.05% Tween, and substrate 3,3',5,5'-tetramethylbenzidine (TMB) (SeramunBlau slow, Seramun
Diagnostika, Heidesee, Germany) was added. The color reaction was stopped with 0.25 M sulfuric
acid, and the absorption was determined at 450 nm (referenced to 620 nm) using a microtiter plate
reader (LP400; Anthos Labtec, Wals, Austria).
2.5. In-Solution Endopep-MS Assay
The in-solution Endopep-mass spectrometry (Endopep-MS) assay was carried out in a 20 µL reaction
volume containing 50 mM HEPES (pH 7.3), 25 mM dithiothreitol, 20 mM (300 µM for BoNT/B) ZnCl2,
1 mg/mL BSA, 0.1 mM peptide substrate (for BoNT/A: Biotin-KGSNRTRIDQGNQ-RATR(Nle)LGGK-
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Biotin (m/z 2878.5); for BoNT/B: LSELDDRADALQAGASQ-FETSAAKLKRKYWWKNLK
(m/z 4037.4); for BoNT/E: IIGNLRHMALDMGNEIDTQNRQIDR-IMEKADSNKT (m/z 4041.5); the
cleavage site is indicated by a hyphen). Peptides were synthesized by Petra Henklein (Institute for
Biochemistry, Charité Universitätsmedizin, Berlin, Germany). BoNT/A or BoNT/E were diluted in
HPLC-water to concentrations of 2 ng/µL, 200 pg/µL, 20 pg/µL and 2 pg/µL (BoNT/B: 600 pg/µL,
60 pg/µL, 6 pg/µL and 0.6 pg/µL). One µl of each toxin dilution and one µL of the substrate solution
were added to 18 µL reaction buffer, and the different resulting 20 µL solutions were incubated for
17 h (4 h BoNT/B) at 37 ˝C. Control reactions lacking BoNT were run at the same time as the analytic
blank. Cleavage products were further desalted and concentrated with ZipTip C18 resin (Merck
Millipore, Darmstadt, Germany), carried out according to the manufacturer's instructions.
MALDI-TOF/TOF-MS: Sample analysis (BoNT/A and E) was done in positive ion reflectron
mode utilizing an autoflex speed MALDI-TOF/TOF mass spectrometer (Bruker Daltonics, Bremen,
Germany) equipped with a smart beam laser. A one µL sample was mixed with 1 µL MALDI-matrix
(12 mg/mL α-cyano-4-hydroxycinnamic acid (Bruker Daltonics) in 0.1% trifluoroacetic acid (TFA)
and 70% acetonitrile in water), and 1 µL was deposited on a polished steel MTP 384 target plate
(Bruker Daltonics). For matrix suppression, deflection was set to 700; mass spectra were acquired over
the mass range m/z 700–4200. External calibration was performed with peptide calibration standard
II (Bruker Daltonics). Each spectrum is an average of 5000 laser shots. Spectra were processed by
flexAnalysis 3.4 software (Bruker Daltonics, 2011). Alternatively, sample analysis (BoNT/B) was
done in positive ion reflectron mode utilizing an Axima Confidence MALDI-TOF mass spectrometer
(Shimadzu GmbH, Reinach BL, Switzerland). A 2 µL sample was mixed with 18 µL MALDI-matrix
(10 mg/mL α-cyano-4-hydroxycinnamic acid in 0.1% TFA and 70% acetonitrile in water), and 0.5 µL
was deposited on a gold well plate (Thermo Fisher Scientific, Reinach, Switzerland). Pulse extraction
was optimized at 4000 Da; mass spectra were acquired over the mass range m/z 1000–5000. External
calibration was performed with peptide C104 Peptide Mix (LaserBioLab, Sophia-Antipolis Cedex,
France). Each spectrum is an average of 1000 laser shots. Spectra were processed by Launchpad
software version 2.9.3 (Shimadzu GmbH, 2011).
2.6. Amino Acid Analysis by Liquid Chromatography-Isotope Dilution Tandem Mass
Spectrometry (LC-IDMS)
BoNT/A, B and E were hydrolyzed by hydrochloric acid and, thus, inactivated, as verified by
the mouse phrenic nerve (MPN) hemidiaphragm assay. AAA was performed as described in Working
Instruction D-00604/1 of the Institute of Reference Materials and Measurements (IRMM), based on
Muñoz et al. [27]. Briefly, the sample is hydrolyzed with 6 M hydrochloric acid in the presence of
phenol by using accelerated microwave digestion at 150 ˝C and high pressure. AA are then separated
and detected by LC-MS/MS. Quantification is based on using pure AA for calibration and the
isotopically-labeled analogues as internal standards. The purity of the AA calibrants was investigated
for the presence of water, organic and inorganic impurities using validated methods. The following
deviations from the validated method were made: (1) all pipetting work was performed in a laminar
flow cabinet for safety reasons; (2) sample preparation was done by volume using calibrated pipettes
and not by weight; calibration solutions, however, were prepared by weight; (3) the volume of toxin,
internal standard and buffer solutions per analysis was proportionally lowered to be able to perform
six repetitions; and (4) an analysis of a sample blank (sample, spiked with isotopically-labeled AA,
hydrolysis omitted), usually included as a quality control sample before the analysis of unknowns,
was not performed for safety reasons.
2.7. Immunological Detection and Quantification by Sandwich-ELISA
For comparison of recombinantly-expressed highly purified BoNT materials with native
toxins purified from C. botulinum supernatants, commercially available 150 kDa BoNTs
(Metabiologics Inc., Madison, WI, USA) were used: BoNT/A1 (Lot #A110911-01; specific activity
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2.7 ˆ 108 LD50/mg), BoNT/B1 (Lot #B110911-01; 1.2 ˆ 108 LD50/mg), BoNT/E3 (Lot #E110911-01;
3.0ˆ 105 LD50/mg; trypsin-activated QC sample 6.0ˆ 107 LD50/mg) and BoNT/F1 (Lot #F110911-01;
1.9 ˆ 107 LD50/mg). Prior analysis of the commercial, native BoNT serotypes by RKI had shown
a purity of 90%–95%, estimated by SDS-PAGE. The protein concentration was determined by
measurement of absorption at 280 nm, 260 nm and 320 nm; however, the individual extinction
coefficient ε used for each BoNT serotype was not provided in the data sheet, so the validity of the
protein concentration of native BoNT was unclear. Highly purified BoNT/A, B and E generated
in this work were tested against the native, commercial BoNT/A, B and E3 in a sandwich-ELISA
approach where both materials were used in equivalent concentrations (100 ng/mL to 0.01 pg/mL;
based on the concentration determined photo-spectrometrically at 280 nm, 260 nm and 320 nm using
the Implen© nanophotometer (Munich, Germany) for the commercial material and based on AAA for
the recombinant material).
The sandwich-ELISAs were performed using capture and biotinylated detection antibodies
followed by a streptavidin-poly-horseradish peroxidase conjugate (PolyHRP40). The following
combinations of monoclonal or polyclonal antibodies (coating antibody/detection antibody),
BoNT/A, A1688/HCA78-biotin; BoNT/B, B279/polyclonal horse trivalent anti-BoNT/A, B
and E Botulism-Antitoxin Behring biotinylated; BoNT/E, KE97 (rabbit polyclonal antibody,
RKI)/E136-biotin, were used (RKI in-house mAb developed in mice, unless otherwise specified).
Briefly, MaxiSorp microtiter plates were coated with primary mAb (10 µg/mL) in 50 µL PBS
overnight at 4 ˝C and blocked with casein buffer (Senova, Jena, Germany) for 1 h at room
temperature. Following washing, 50 µL of toxin was added in serial dilutions from 100 ng/mL
to 0.01 pg/mL in assay buffer (PBS, 0.1% BSA (Sigma-Aldrich) and incubated for 2 h at room
temperature. The sandwich ELISA was developed by incubation with biotin-labeled secondary
antibody diluted in casein buffer (1 h, room temperature), followed by washing and detection with
Streptavidin-PolyHRP40 (0.5 ng/mL, Senova) and substrate TMB.
2.8. Mouse Phrenic Nerve Hemidiaphragm (MPN) Assay
The MPN assay was performed as described previously [28,29]. To limit the consumption
of mice, the left and right phrenic nerve hemidiaphragms were excised from female mice of
strain RjHan:NMRI (18–25 g, Janvier, St Berthevin Cedex, France) and placed in an organ bath
containing 4 mL of Earle's Balanced Salt Solution. The pH was adjusted to 7.4, and oxygen
saturation was achieved by gassing with 95% O2 and 5% CO2. The phrenic nerve was continuously
electro-stimulated at a frequency of 1 Hz via two ring electrodes. The pulse duration was 0.1 ms,
and the current was 25 mA, to achieve maximal contraction amplitudes. Isometric contractions were
recorded with a force transducer (Scaime, Annemasse, France) and the software VitroDat version 3.6.1
(Föhr Medical Instruments GmbH (FMI), Seeheim, Germany). The resting tension of the diaphragm
was approximately 10 mN. In each experiment, the preparation was first allowed to equilibrate for
15 min under control conditions. Then, the buffer was changed to 4 mL of Earle's Balanced Salt
Solution supplemented with 0.1% BSA, and the toxin-containing solution was added (BoNT/A–F).
Toxin concentrations were such to allow the reduction of the contraction amplitude by 50% between
50 and 150 min. The times required to decrease the amplitude by 50% (paralysis time t½ ď180 min)
at different BoNT concentrations were used to construct the calibration curves for BoNT/A–F. These
logarithmic functions were fitted to the calibration curves:
y (BoNT/A; 0.408/0.81/1.63 pM) = ´16.062Ln(x) + 60.648, R2 = 0.99;
y (BoNT/B; 2.40/4.80/9.61 pM) = ´10.928Ln(x) + 83.967, R2 = 1.0;
y (BoNT/C; 2.73/5.47/10.94/21.88/43.76 pM) = ´21.232Ln(x) + 137.993, R2 = 0.994;
y (BoNT/D; 0.388/1.16/1.94/3.88 pM) = ´18.893Ln(x) + 83.032, R2 = 0.998;
y (BoNT/E; 2.04/4.08/8.15 pM) = ´23.612Ln(x) + 104.11, R2 = 1.0;
y (BoNT/F; 25.77/36.81/73.62/110.4/147.2 pM) = ´17.325Ln(x) + 143.327, R2 = 0.998.
5040
Toxins 2015, 7, 5035–5054
Normalized potency was calculated by converting the 70-min paralytic half-time to the
corresponding BoNT concentrations employing the above equations and referenced to the least active
BoNT/F.
2.9. Mouse Bioassay (MBA)
The biological activity of the produced BoNTs was determined in mouse median lethal dose
(LD50) [30,31]. The mouse LD50 bioassay is a quantitative method that determines the dose which
would kill half of the tested animals (mice) at day 4 after injecting the toxin into the peritoneal
cavity. The unit (U) of biological activity of botulinum toxin is defined as the LD50 of the BoNT
in a population of mice (1.0 LD50 = 1.0 U). Female mice of Charles River Laboratories:Oncins
France 1 (Crl:OF1) outbred strain (weighing 18–20 g each) were purchased from Charles River
(Chatillon-sur-Chalaronne, France). The test was approved by the Belgian Ethical Committee on
Animal Experiment at Scientific Institute of Public Health-Veterinary and Agrochemical Research
Centre (IPH-VAR, Reference Number 20130409-01). Received BoNT/A (114 µg/mL), BoNT/B
(20.2 µg/mL), BoNT/E (156 µg/mL) and BoNT/F (77 µg/mL) were aliquoted and stored at ´80 ˝C
until further use. Each experiment was conducted using a new aliquot of toxin diluted in PBS, 0.1%
BSA, pH 7.4. Assays were performed using 5 dilutions of toxin and 10 mice per dose. Dilutions were
increased in a geometric progression, and the ratio between successive doses was 1.4. Diluted BoNT
samples were administered intraperitoneally to mice (n = 10; volume injected per mice was 0.5 mL).
Injected mice were observed during 4 consecutive days. Symptoms of botulism and death induced
in mice were recorded. The acute toxicity of BoNT was determined by the calculation of LD50 [30].
Briefly, the percentage of death among the mice was determined for each dose of toxin. It is assumed
that a mouse that survives at a given toxin dose would have survived at a lower dose and that a mouse
that dies at a given dose would have died at any higher dose. The total of dead and alive mice and
the percentage of mortality are calculated at each dose of toxin injected. The proportional distance
from LD50 is then calculated from the dilution above and the dilution below the dilution, which gave
50% mortality: proportional distance = (50%´%mortality at dilution below)/(%mortality at dilution
above´%mortality at dilution below); log LD50 = log of concentration below + (proportional distance
ˆ log dilution factor).
3. Results
3.1. Production of Highly Purified BoNT/A–F
The 150 kDa di-chain BoNT, which can form stable PTCs of varying sizes with the non-toxic
NAPs in an environment of pH < 6.5, is the fully-active toxicological entity, is well defined and
constitutes the target analyte for unambiguous diagnostic results. Since the composition of high
molecular weight PTCs varies depending on sero- and subtype (and corresponding strain), as well
as environmental conditions, 150 kDa BoNT/A1–F1 prototypes were chosen to serve as RM (Table 1;
for simplicity, subtype nomenclature is not indicated anymore from here on). To ensure the absence
of clostridial host proteins, the BoNT RMs were produced by means of recombinant techniques in
E. coli. This approach also facilitates handling of the GMMO with respect to biosafety and allows
reproducible culturing. The coding sequences (CDS) of BoNT/A-F were either amplified by PCR or,
if necessary, synthesized with codon usage optimized for expression in E. coli [32–34]. At the 3'-end,
a CDS of His- and/or Streptag affinity tags fused to a thrombin recognition site was added to ensure
efficient affinity purification and tag removal. Since only di-chain BoNT displays functional activity
in neurons, a posttranslational proteolytic activation of scBoNT is mandatory to obtain maximum
active BoNT. For this purpose, the CDS of another thrombin recognition site was inserted into the
CDS of the loop region connecting LC and HC [35].
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Table 1. Characteristics of the recombinant BoNT reference material.
BoNT
Serotypes















BoNT LC HC SDS-PAGE CGE CGE AAA
SDS-
PAGE #
(Da) (Da) (Da) (%) (%) (%) (mg/mL) (mg/mL) (µM) - (pg/mouse) - (U/mg)
BoNT/A M30196 AAA23262 150,266 51,093 99,190 97 99 99.9 0.114 ˘0.007 n.d. 0.759 123 7.01 ˘ 0.53 6.9 1.43 ˆ 108
BoNT/B M81186 AB232927 152,953 52,341 100,630 100 100 96.0 0.0202 ˘0.0023 n.d. 0.132 19.2 20.22 ˘ 1.39 2.4 0.49 ˆ 108
BoNT/C X53751 CAA37780 149,770 51,561 98,226 95 n.d. n.d. n.d. n.d. 0.308 2.054 2.80 n.d. n.d. n.d.
BoNT/D X54254 CAA38175 148,106 51,216 96,907 88 n.d. n.d. n.d. n.d. 0.092 0.620 34.6 n.d. n.d. n.d.
BoNT/E X62089 CAA43999 144,776 48,282 96,512 92 95 93.0 0.156 ˘0.017 n.d. 1.078 16.2 24.49 ˘ 0.56 2.0 0.41 ˆ 108
BoNT/F X81714 CAA57358 148,201 50,053 98,165 90 97 ~90 n.d. n.d. 0.085 0.572 1 48.21 ˘ 1.13 1 0.21 ˆ 108
# Protein concentrations of BoNT/C, D and F were determined by SDS-PAGE, Coomassie brilliant blue staining and densitometry using BoNT/A, B and E, whose protein
concentrations were assigned by AAA as standard proteins. n.d., not determined.
5042
Toxins 2015, 7, 5035–5054
All six BoNTs were readily expressed and could be isolated in acceptable to excellent yields
as single chain polypeptides by one-step affinity chromatography. Digest with thrombin and
subsequent gel filtration yielded highly pure di-chain BoNT/A–F (Figure 1). Western blot analysis
using anti-His6tag and anti-Streptag mAbs revealed complete removal of C-terminal affinity tags.
SDS-PAGE analysis under reducing and non-reducing conditions revealed 88%–100% specific
proteolysis into 50 kDa LC and 100 kDa HC (Table 1) and the absence of any degradation products.
Incorrect proteolysis outside the loop and, thus not encompassing the disulfide bridge would have
resulted in toxin fragments not connected under oxidizing conditions to the remaining BoNT part.
Furthermore, the disulfide bridge is quantitatively formed without artificial oxidation, as exemplified
for BoNT/A, B, E and F. The theoretical molecular weight of the full-length BoNT ranges from
144.7 kDa (BoNT/E) to 152.9 kDa (BoNT/B) (Table 1). Oxidizing SDS-PAGE resembles this order
with the exception of BoNT/A migrating at lower molecular weight (MW) than BoNT/E (Figure 1).
Under reducing conditions, the HCs of all BoNTs display a similar pattern around 95–100 kDa. For
LC, the main differences in reduced SDS-PAGE compared to theoretical MW are seen for LC/B (too
low) and LC/F (too high) (Figure 1; Table 1). The stability of BoNT/A–E in solution was good, but it
turned out that BoNT/F tends to precipitate significantly upon freeze-thaw cycles, which was cured
by the addition of 0.1% BSA.
Figure 1. SDS-PAGE analysis of BoNT/A–F. Final products of BoNT/A–F were analyzed under
reducing conditions by 10% SDS-PAGE and detected via Coomassie brilliant blue (left panel). All
BoNTs displayed ď12% scBoNT under reducing conditions. One microgram of the final products
BoNT/A, BoNT/B, BoNT/E and BoNT/F was analyzed under reducing and oxidizing conditions by
4%–15% gradient SDS-PAGE and detected via Coomassie brilliant blue (right panel). Quantitative
formation of the disulfide bridge is demonstrated for all four proteins. The multiple protein bands in
BoNT/F are derived from 0.1% BSA as a supplement to stabilize BoNT/F.
3.2. Analysis of Purity, Degree of Activation and Molecular Weight by Capillary Gel Electrophoresis
The four serotypes BoNT/A, B, E and F pathogenic to humans were given highest priority.
Therefore, they were additionally analyzed with respect to purity, degree of activation and molecular
weight by CGE. The purity of BoNT/A, B and E ranged from 93% to 99.9% (Table 1). The addition of
0.1% BSA impaired precise analysis of BoNT/F, and its purity was estimated to 90%. CGE analysis of
reduced BoNT samples showed that the scBoNT was ď5% for all four BoNT serotypes (Figure 2 and
Table 1), confirming data from SDS-PAGE analysis (Figure 1). In contrast to SDS-PAGE analysis, the
deduced MW of oxidized BoNT/B, E and F in CGE was 30–40 kDa higher than the theoretical MW.
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Upon reduction, all LCs displayed an MW similar to their theoretical reference mass, whereas HC of
BoNT/B, E and F displayed an MW increased by 10–25 kDa.
Figure 2. CGE analysis of BoNT/A, B, E and F. Non-reduced (top panel) and reduced (bottom panel)
BoNT/A, B, E and F were analyzed by CGE. Contaminations were concluded from repeated analysis
and are highlighted in blue circles (top). BSA-related peaks are visible in BoNT/F samples. Trace
amounts of un-nicked scBoNT (*; bottom) were detected in BoNT/A, BoNT/E and BoNT/F, whereas
BoNT/B was quantitatively hydrolyzed. LM = 1.2 kDa lower marker; IB = instrument background;
LC = light chain; HC = heavy chain; UM = 260 kDa upper marker.
3.3. Verification of Protein Sequence Identity by Tryptic Fingerprinting and LC-MS/MS Sequencing
The identity of BoNT/A, B, E and F was verified by tryptic fingerprinting and peptide
sequencing by LC-MS/MS. Multiple serotype-specific peptides were identified in all four digestions,
and the identified peptides were well distributed over both HC and LC with a sequence coverage
ranging from 33% to 50% (Table 2). For BoNT/A, the analysis also revealed parts of the sequence
that differ in the recombinant toxin compared to the native one, i.e., the loop peptide containing
the thrombin cleavage motif at the end of the LC. Furthermore, the BoNT/A1-determining peptide
from the LC was detected, containing an alanine at position 26. When using non-reducing conditions
during the trypsin digestion, the intact disulfide linkage between the LC and HC of BoNT/A could
also be demonstrated, which is in accordance with SDS-PAGE and CGE data.
Table 2. Summary of LC-MS/MS results. The identification of BoNT/F peptides suffers from the BSA
background in the sample.
Sample Number of Peptides Identified (of Total) Identified Peptides in HC Identified Peptides in LC
BoNT/A 68 (48%) 39 29
BoNT/B 74 (47%) 44 30
BoNT/E 64 (50%) 48 16
BoNT/F 43 (33%) 30 13
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Figure 3. Detection of BoNT/A, B, E and F by indirect ELISA using a set of different antibodies.
BoNT/A (top left), BoNT/B (top right), BoNT/E (bottom left) and BoNT/F (bottom right) were coated
as the antigen (each 500 ng/mL) in 50 µL PBS/0.1% BSA and tested against different anti-BoNT/A-,
B-, E- and F-specific antibodies; antibody names are indicated below the panels, the serotype
specificity of the antibodies is indicated by A, B, E or F, respectively. “Behring” is a polyclonal horse
trivalent anti-BoNT/A, B and E Botulism-Antitoxin; “mix” indicates a polyclonal serum from mice
immunized in parallel with BoNT/A, B, E and F (positive control).
3.4. Detection of BoNT/A, B, E and F by Indirect ELISA
A panel of specific polyclonal and monoclonal anti-BoNT/A, B, E and F antibodies was
employed to detect the highly purified BoNT/A, B, E and F by indirect ELISA (Figure 3). Overall,
the reactivity of the Abs used was as expected from the serotypes tested and from the specificities
of Abs, as determined from previous experiments. In particular, the reactivity of the monoclonal
antibodies A709, HCA78, A1688 (all three directed against BoNT/A), B279 (directed against BoNT/B),
E136 (directed against BoNT/E) and F220 (directed against BoNT/F) demonstrated that the sample
contained the desired serotype (Figure 3). No evidence for cross-contamination with other serotypes
was observed. A few of the polyclonal antibodies showed a certain degree of cross-reactivity between
the serotypes, e.g., HF58, a polyclonal chicken IgY directed against BoNT/F, also weakly recognized
BoNT/A, B and E, while trivalent anti-BoNT/A, B and E Botulism-Antitoxin Behring also detected
BoNT/F, the closest relative of BoNT/E. In the case of HE57, a polyclonal chicken IgY directed against
BoNT/E, the most similar serotypes BoNT/A and BoNT/F, but not the much less related BoNT/B,
was detected to some extent.
3.5. Determination of BoNT/A, B and E Catalytic Activity by Endopep-MS Assay
The Endopep-MS assay is a rapid and sensitive detection method for differentiating
catalytically-active BoNT serotypes [36–39]. The principle of this method is that BoNTs recognize
and cleave a unique site of the synaptic SNARE proteins SNAP-25, Syntaxin -1A/-1B or
synaptobrevin/VAMP-1/-2, and the resulting cleaved peptide products are detected by mass
spectrometry. Here, Endopep-MS was used to test the in vitro catalytic activity of BoNT/A, B and
E in serial dilutions on synthetic, truncated peptides. Cleaved peptide products were analyzed by
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MALDI-TOF/TOF MS (Figure 4). BoNT/A, cleaving the Q197-R198 peptide bond in SNAP-25, yielded
specific cleavage products with m/z 1699.9 (N-terminal product, Biotin-KGSNRTRIDQGNQ) and m/z
1197.8 (C-terminal product, RATR(Nle)LGGK-Biotin) (Figure 4A). In contrast, BoNT/B proteolyzes
VAMP-1/-2 at Q76-F77, which results in the cleavage products m/z 1759.7 (N-terminal product,
LSELDDRADALQAGASQ) and m/z 2296.7 (C-terminal product, FETSAAKLKRKYWWKNLK)
(Figure 4B). For BoNT/E, which also hydrolyzes SNAP-25, but between R180-I181, the specific
cleavage products with m/z 2923.5 (N-terminal product, IIGNLRHMALDMGNEIDTQNRQIDR) and
m/z 1136.7 (C-terminal product, IMEKADSNKT) were identified (Figure 4C). Hence, all three BoNTs
exerted their expected specific catalytic activity in vitro on artificial synaptic SNARE substrate-based
peptides. Similar results were obtained for native BoNT/A, B and E. Endopep-MS analysis of
BoNT/A mixed with BoNT/B- and E-specific peptides did not yield any cleavage product.
Analogous approaches with BoNT/B and E also showed no sign of cleavage products evidencing
the absence of BoNT cross-contamination.
Figure 4. Cont.
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Figure 4. Endopep-MS assay of BoNT/A, B and E. (A) Mass spectra of the in-solution activity assay
with BoNT/A. Endopep reaction buffer was spiked with 200 pg BoNT/A (upper panel) and without
(lower panel). The substrate peak (m/z 2878.5), N-terminal (m/z 1699.9) and C-terminal (m/z 1197.8)
cleaved peptide products from BoNT/A substrate are labeled; (B) Endopep reaction buffer was spiked
with 60 pg BoNT/B (upper panel) and without (lower panel). The substrate peak (m/z 2019.7),
N-terminal (m/z 1759.7) and C-terminal (m/z 2296.8) cleaved peptide products from the BoNT/B
substrate are labeled; (C) Endopep reaction buffer was spiked with 200 pg BoNT/E (upper panel)
and without (lower panel). The substrate peak (m/z 4041.5), N-terminal (m/z 2923.5) and C-terminal
(m/z 1136.7) cleaved peptide products from the BoNT/E substrate are labeled. Inserts show the isotope
peak pattern of cleaved peptides if detectable. The occurrence of only the C-terminal peptide fragment
in the BoNT/E control sample is due to an instability of this peptide substrate, which was already
previously recognized [40,41]. To circumvent this signal, very recently, an optimized peptide substrate
for BoNT/E was introduced by incorporating a non-natural homo-arginine residue at P1 position (first
AA position upstream of the cleavage site), as well as introducing C-terminal amidation of the peptide
substrate, which significantly reduced unspecific cleavage and increased peptide stability [41].
3.6. Determination of Protein Concentration of BoNT/A, B and E by AAA
The accurate determination of the amount of protein substance is of crucial importance. Protein
concentration determinations based on the measurement of absorption at 278 nm, 260 nm and 320 nm
require sufficiently high concentrations in the case of BoNT and the knowledge of the individual
extinction coefficient of each BoNT variant. Only for L-PTC/A, an A260/A278 ratio of <0.6 and an
extinction coefficient ε (278 nm) = 1.65 mL¨ cm´1¨mg´1 and ε (280 nm) = 1.54˘ 0.26 mL¨ cm´1¨mg´1,
respectively, are known [42,43], but no value is reported for PTCs of other serotypes or pure
150 kDa BoNTs. In addition to the classical methods by Biuret [44], Bradford [45], Lowry [46]
and Kjeldahl [47], protein quantification can be achieved using isotopic dilution mass spectrometry
(IDMS) [27]. Here, the BoNT proteins were completely hydrolyzed into their principal components,
the AA. Subsequently, six AA (alanine, proline, valine, leucine, isoleucine and phenylalanine) were
quantified based on IDMS. Knowledge of the purity and AA sequence composition of the protein
of interest allows calculation of the results. The calculations are based on the quantity of individual
amino acids present in the solution. The protein preparation to be analyzed with this method needs to
be sufficiently pure, otherwise results cannot be related to the theoretical sequence of a given protein
and, thus, are meaningless. The protein purity was considered when calculating the concentrations
of highly purified BoNT (Table 1): whereas for BoNT/A, the purity assessment by CGE did not reveal
any protein (AA containing) impurities in the sample, the CGE purity assessment of the BoNT/B and
BoNT/E preparations revealed protein purities of 96% and 93%, respectively (Table 1). BoNT/F had
to be excluded due to the addition of 0.1% BSA for stabilization purposes.
3.7. Comparison of Recombinant versus Native BoNT/A, B and E by Sandwich-ELISA
Due to the fact that there is no qualified BoNT RM available, commercial native 150 kDa
BoNT/A, B and E3 purified from C. botulinum culture supernatant were compared to the recombinant
5047
Toxins 2015, 7, 5035–5054
BoNT/A, B and E material produced here by serotype-specific sandwich-ELISA. It has to be kept
in mind that the protein concentration of the commercial BoNT determined by the measurement
of absorption at 280 nm, 260 nm and 320 nm is not a thoroughly-validated value and was, to
the best of our knowledge, not checked by AAA. Still, for an experimental comparison of the
recombinant material produced in this work with the native BoNT, the native BoNT, based on the
concentration determined by the measurement of absorption, was used in the same concentrations
as the recombinant BoNT in serotype-specific sandwich-ELISA. As shown in Figure 5, equivalent
concentrations of either native or recombinant BoNT/A, B and E provide very similar results. A
precise quantification of the recombinant material versus the native BoNT was not performed due
to the lack of precise experimental extinction coefficients ε for the differently purified 150 kDa
BoNT serotypes and the inaccuracy associated with this value. Instead, AAA was used for precise
quantification, since it is known to deliver more precise results than photometric measurement.
Therefore, the values obtained by AAA as the most precise concentrations of the highly purified
BoNT materials formed the basis for future experiments.
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Figure 5. Comparison of recombinant, highly purified BoNT/A, B and E with native BoNT/A, B and
E3 using serotype-specific sandwich-ELISA. Coating antibodies and biotinylated detection antibodies
were used in a classical sandwich-ELISA format, as described above; the signal obtained by bound
antigen was amplified and detected using a streptavidin-PolyHRP40 conjugate and TMB substrate.
The absorption was plotted against the logarithmic concentrations of BoNT.
3.8. De erminatio of BoNT/A-F Potency by the MPN Assay
The isolated mouse phrenic nerve (MPN) hemidiaphragm assay is an ex vivo method examining
the full physiological pharmacodynamic of BoNT by closely reproducing in vivo respiratory
failure [29,33,48–50]. The time period between application of BoNT into the organ bath and halved
contraction amplitude correlates with BoNT efficacy and potency, as well as its concentration
compared to a BoNT standard material. It has been demonstrated that the paralysis time correlates
with the toxicity (MLD, LD50, units) determined by the MBA [51]. Here, concentration response
curves of all six BoNT/A-F were established, a d logarithmic functions were fitted with excellent
R2 valu (Figure 6). The potency of BoNT/A is the highest, followed by the group of BoNT/D, B
and E. BoNT/C a d BoNT/F displayed the lowest potency. Employing the logarithmic functions,
the concentration of each BoNT serotype causing 70 min paralytic halftime was calculated and
normalized to BoNT/F, which displays the lowest potency (Table 1). BoNT/C is ~3-fold more potent
than BoNT/F, whereas BoNT/A is 120-fold more potent. BoNT/D is only 3.5-fold less potent than
BoNT/A, but 35-fold more potent than BoNT/F. BoNT/B and BoNT/E display medium potencies.
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Figure 6. Ex vivo mouse phrenic nerve (MPN) hemidiaphragm assay of BoNT/A–F. Concentration
response curves were generated based on three to five BoNT concentrations measured in triplicate to
quintuplicate. The calculated mean ˘ SD of the paralytic halftime t½ was plotted against the protein
concentration. Logarithmic functions were fitted yielding excellent R2 values.
3.9. Determination of Biological Activity by Mouse Bioassay
For decades, the MBA determining the median lethal dose (LD50) of BoNT in mice has
represented the gold standard among various biological, chemical or immunological detection
systems for BoNT [5,14]. The MBA has been accepted by pharmaceutical regulatory agencies
worldwide to test the potency of BoNT pharmaceuticals [52,53]. However, it comprises some
disadvantages: the MBA is costly, lasts for a long period (up to several days in the case of the
diagnostics of BoNTs), and most importantly, many mice suffer from botulism and die painfully by
respiratory failure due to flaccid paralysis of the diaphragm muscles, which represents its major end
point [54]. However, in contrast to the MPN assay, the MBA describes the pharmacodynamics and
-kinetics of BoNT. The LD50 data presented in Table 1 show the calculated mean LD50 ˘ SD from
three independent experiments. These experiments were performed using five dilutions of toxin, a 1.4
ratio between successive doses and 10 mice per dose. The calculation of LD50 revealed 7.01 ˘ 0.53 pg
BoNT/A, 20.22 ˘ 1.39 pg BoNT/B, 24.49 ˘ 0.56 pg BoNT/E and 48.21 ˘ 1.13 pg BoNT/F. Again,
BoNT/A displayed the highest biological activity; BoNT/B and E exhibited similar and BoNT/F the
lowest biological activity. The coefficients of variation (CV) differed between 2.3% and 7.6%, which
suggests that the LD50 were determined with a high degree of precision.
4. Discussion
In light of the dual-use potential of BoNT, the evaluation of existing methods for screening and
identification of BoNTs is of major importance to the European Union. Hence, one main aim of the
EQuATox consortium was to conduct an international BoNT PT to provide such information, but the
task was seriously hampered by the lack of qualified BoNT RM. Therefore, highly purified BoNT had
to be generated and qualified as RM to serve as spiking material for the BoNT PT. The recombinant
expression of BoNT provides several advantages compared to isolation of BoNT from C. botulinum
culture supernatants (detailed above). Here, the six serotypes BoNT/A–F were successfully produced
in good to excellent yields and purity by similar purification protocols. In addition, the specific
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proteolysis of the recombinant scBoNT into LC and HC was achieved depending on the serotype
almost quantitatively, with a yield of 88%–100%. This is in contrast to partial proteolysis occurring,
e.g., in BoNT/B due to its short loop sequence or complete absence of proteolysis in BoNT/E subtypes
due to the non-proteolytic C. botulinum Group II and C. butyricum strains. Quantitative proteolysis
allows the direct comparison of all highly purified BoNT with respect to potency and biological
activity without significant influences by different culturing conditions, purification protocols and
varying degrees of activation.
The four serotypes causing botulism in humans, BoNT/A, B, E and F, were prioritized and
thoroughly characterized by various methods. All four highly purified BoNTs were detected and
unambiguously identified by means of immunological and different MS-based methods. Validated
AAA precisely determined protein concentrations of BoNT/A, B and E, which subsequently allowed
the reliable determination of specific activity.
In this study, the normalized potency of BoNT/A determined relative to BoNT/F in the MPN
assay is 120-fold higher, whereas BoNT/D is only 3.5-fold less potent than BoNT/A, but 35-fold
more potent than BoNT/F. BoNT/B and BoNT/E display medium potencies, while BoNT/C is just
~3-fold more potent than BoNT/F. This order of potency largely resembles that of the specific activity
of native purified 150 kDa BoNT/A–F (relative specific activity: BoNT/A 10, BoNT/B 11, BoNT/C
1.8, BoNT/D 10, scBoNT/E 1, BoNT/F 2.4) [55], indicating correct folding and maturation of the
recombinant proteins by the developed purification process. Potency is proportional to the affinity
and efficacy of a drug; in the case of BoNT, modulation of one of its multiple steps in the mode of
action (binding, uptake, translocation and catalytic activity) has been shown to influence its potency
in either way [32,35,56–59]. Along this line, the isolated LC/D and LC/F display similar kcat/KM
values of ~0.8 µM´1 s´1 on VAMP-2 [60], but in this study, BoNT/D is 35-fold more potent than
BoNT/F, which might be due to differences in binding, uptake and translocation. Even the champion
BoNT/A exhibited room for improvement of potency by exchanging its binding domain HC against
that of BoNT/B [35].
The native purified 150 kDa di-chain BoNTs all display high specific toxicities, from
107–108 LD50/mg of protein with BoNT/E and F at the lower end of the scale, although the
relationships might not be the same in different animal species. Comparison of the specific activity
of the highly purified BoNT/A, B, E and F with published LD50 data (BoNT/A 1.05 ˆ 108 ´ 1.86 ˆ
108 LD50/mg, BoNT/B 0.98 ˆ 108 ´ 1.14 ˆ 108 LD50/mg, BoNT/C 0.88 ˆ 108 LD50/mg, BoNT/D
1.60 ˆ 108 LD50/mg, BoNT/E 0.21 ˆ 108 ´ 0.25 ˆ 108 LD50/mg, BoNT/F 0.16 ˆ 108 ´ 0.40 ˆ
108 LD50/mg [61]) and data accompanying commercially available BoNT (see Section 2.7) shows
that the recombinantly produced BoNTs are at least as active as BoNTs isolated from C. botulinum.
Quantitative sandwich-ELISA confirmed the equivalence of recombinant and native BoNT/A, B
and E.
Native BoNT/F is very often released in minute quantities by C. botulinum and displays
moderate biological activity. Recombinant expression of BoNT/F overcame such problems for
the first time and provided satisfactory amounts of quantitatively-activated BoNT/F, which was
confirmed by its high biological activity. However, the stability of the BoNT/F protein was limited
upon freeze-thaw cycles and could only be compensated by the addition of 0.1% BSA. Such a
proteinaceous stabilizer impeded the characterization by CGE and MS, as well as obviated the
determination of the protein concentration by AAA. In the future, the stability and solubility of
the BoNT/F molecule have to be improved, and a non-AA based stabilizer compatible with the
characterization methods should be developed.
The comparison of potency determined by the ex vivo MPN assay with biological activity
obtained by the MBA yielded a similar order of functional activity for BoNT/A, B, E and F. In contrast
to the 120-fold potency difference between BoNT/A and F determined by the MPN assay, the MBA
revealed only a seven-fold difference in specific activity. This difference could be explained by the fact
that the in vivo MBA describes the pharmacodynamics plus the pharmacokinetics of BoNT, which
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includes different factors like absorption, distribution, metabolism or elimination from circulation
of the individual BoNTs, while factors, such as distribution, metabolism or elimination, are not
displayed in the MPN assay.
5. Conclusions
In conclusion, highly purified BoNT/A–F were successfully produced by recombinant means
and characterized with respect to purity, identity, protein concentration, in vitro catalytic activity,
potency and specific activity. Results from characterization studies qualified the highly purified
BoNT as a reference material suitable to serve as a spiking material for samples to be analyzed in
an international BoNT PT organized by the EQuATox consortium [15].
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